Nivolumab or pembrolizumab should be added to standard chemotherapy to prolong the life of patients with gastric, esophageal, and gastroesophageal junction cancers.
Nivolumab or pembrolizumab should be added to standard chemotherapy to prolong the life of patients with gastric, esophageal, and gastroesophageal junction cancers.